DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

University Hospitals (UH)

Status and phase: Terminated; Phase 2

Conditions: Postoperative Ecchymosis

Treatments: Drug: DDAVP

Study type: Interventional

Funder types: Other

Identifiers

NCT01982760

07-10-21

Details and patient eligibility

About

This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.

Enrollment: 14 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Undergoing Rhinoplasty where nasal bone osteotomy is necessary

Exclusion criteria

• Heart Disease
• Renal Disease with decreased GFR
• Liver Disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

14 participants in 2 patient groups

DDAVP

Experimental group

Description:

Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.

Treatment:

Drug: DDAVP

No DDAVP

No Intervention group

Description:

Patients Will not receive DDAVP prior to Rhinoplasty